• 作者：Guillaume Legrand^a ; ^b ; ^{glegrand@chu-clermontferrand.fr} ; Ré ; mi Tourtauchaux^a ; Isabelle Jalenques^a ; ^b
• 关键词：Â ; gé ; Guidelines ; Schizophré ; nie ; Traitement antipsychotique
• 刊名：Annales medico-psychologiques
• 出版年：2012
• 期刊代码：78_00034487
• 类别：psy
• 出版时间：May, 2012
• 卷：170
• 期：4
• 页码：278-282
• 文件大小：207 K

Following studies, comorbid medical conditions are more frequent in old people with schizophrenia so that they have to be taken into account (contraindication, side effects and drug interaction). Furthermore, pharmacocinetics and pharmacodynamics changes are usual during aging and prescription rules are necessary. On the other hand, symptoms are evoluting in people with schizophrenia and must be part of therapeutic management. First generation antipsychotics use has a high risk of parkinson-like side effect and tardive dyskynesia in old patients. Atypical antipsychotics seem to be efficacious in reducing negative symptoms and appear to have a relatively safer adverse effect profile. However, side effects especially metabolic pertubations require particular monitoring. PubMed and ScienceDirect were searched for relevant studies and recent guidelines about atypical antipsychotic in old people with schizophrenia published from 2006 to now. Authors report a review of recent knowledge for second generation antipsychotic prescription in patient suffering from long-standing schizophrenia.